Rita Birne

Mar 20, 2024 | bmjopen.bmj.com | Shweta Bansal |Stefan Anker |George Bakris |Rita Birne

DiscussionThe findings of this post hoc analysis suggest that finerenone reduced the risk of CV and kidney composite outcomes versus placebo across all age and sex subcategories. In FIDELITY, HHF was the main driver of CV benefit with finerenone23; lower incidences of HHF with finerenone versus placebo were observed in this analysis across all age subgroups, with some differences noted between sex subgroups.